Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 11:45 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC
September 26, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...
September 22, 2025 03:50 ET | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
June 24, 2025 02:00 ET | Source: Exact Therapeutics AS

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT...
December 17, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 05, 2024 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
November 27, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
November 13, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 06, 2024 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...
November 05, 2024 09:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...